Table of Contents

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

 


 

FORM 11-K

 

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

(Mark One)

 

x                              ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2018

 

OR

 

o                                 TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                     to                                        

 

Commission File Number 1-2189

 

A.                                    Full title of the plan and the address of the plan, if different from that of the issuer named below:

 

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

 

B.                                    Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

 

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

 

 

 


Table of Contents

 

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN

DECEMBER 31, 2018 AND 2017

 


Table of Contents

 

C O N T E N T S

 

 

Page

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

3

 

 

FINANCIAL STATEMENTS

 

 

 

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

5

 

 

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

6

 

 

NOTES TO FINANCIAL STATEMENTS

7

 

 

SUPPLEMENTAL SCHEDULE

 

 

 

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

18

 


Table of Contents

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Plan Administrator and Plan Participants
Abbott Laboratories Stock Retirement Plan

 

Opinion on the financial statements

 

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2018 and 2017, the related statement of changes in net assets available for benefits for the year ended December 31, 2018, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2018 and 2017, and the changes in net assets available for benefits for the year ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

 

Basis for opinion

 

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

3


Table of Contents

 

Supplemental information

 

The schedule of assets (held at end of year) as of December 31, 2018 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

 

/s/ Grant Thornton LLP

 

We have served as the Plan’s auditor since 2002.

 

Chicago, Illinois
June 27, 2019

 

4


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

December 31, 2018 and 2017

(Dollars in thousands)

 

 

 

2018

 

2017

 

Assets

 

 

 

 

 

Cash

 

$

505

 

$

7,742

 

Investments, at fair value

 

9,807,801

 

7,895,700

 

Notes receivable from participants

 

84,350

 

58,442

 

Accrued interest and dividend income

 

6,958

 

1,598

 

Due from brokers

 

256,213

 

163

 

 

 

 

 

 

 

Total assets

 

10,155,827

 

7,963,645

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

Investments sold short, at fair value

 

219,491

 

 

Accrued investment expenses

 

318

 

327

 

Due to brokers

 

511,309

 

4,521

 

 

 

 

 

 

 

Total liabilities

 

731,118

 

4,848

 

 

 

 

 

 

 

NET ASSETS AVAILABLE FOR BENEFITS

 

$

9,424,709

 

$

7,958,797

 

 

The accompanying notes are an integral part of these statements.

 

5


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

Year ended December 31, 2018

(Dollars in thousands)

 

Additions

 

 

 

Contributions

 

 

 

Employer

 

$

147,621

 

Participant

 

262,781

 

Rollovers

 

66,207

 

 

 

 

 

Total contributions

 

476,609

 

 

 

 

 

Investment income (loss)

 

 

 

Net depreciation in fair value of investments

 

(166,071

)

Interest and dividends

 

245,449

 

 

 

 

 

Net investment income

 

79,378

 

 

 

 

 

Interest income on notes receivable from participants

 

3,324

 

 

 

 

 

Total additions

 

559,311

 

 

 

 

 

Deductions

 

 

 

Benefits paid to participants

 

678,790

 

 

 

 

 

Net decrease prior to transfers

 

(119,479

)

 

 

 

 

Transfers into Plan

 

1,585,391

 

 

 

 

 

NET INCREASE

 

1,465,912

 

 

 

 

 

Net assets available for benefits

 

 

 

Beginning of year

 

7,958,797

 

 

 

 

 

End of year

 

$

9,424,709

 

 

The accompanying notes are an integral part of these statements.

 

6


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS

December 31, 2018 and 2017

 

NOTE A - DESCRIPTION OF THE PLAN

 

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information.  Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

 

General

 

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7).  The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

 

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan.  Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

 

Alight Solutions serves as the record keeper of the Plan.  The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

 

In January 2017, Abbott completed the acquisition of St. Jude Medical, Inc., a global medical device manufacturer.  During 2017, employees of St. Jude Medical, LLC (the surviving entity in the acquisition) and its subsidiaries in the United States were eligible to participate in the St. Jude Medical, Inc. Retirement Savings Plan (“SJM Plan”), not the Plan.  St. Jude Medical employees in the United States became eligible to participate in the Plan as Abbott Green employees effective for the first payroll period ending after January 1, 2018.  On January 19, 2018, the SJM Plan merged with and into the Plan.  Assets totaling approximately $1.6 billion transferred into the Plan.

 

Contributions and Vesting

 

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”).  The Trust is administered by the Trustee and an investment committee (the “Committee”).

 

Employees are eligible to commence participation in the Plan on any entry date following their date of hire.  Eligible employees electing to participate contribute from 2% up to 25% of their eligible earnings, subject to certain limitations.  Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both.  The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature.  Effective for payroll periods ending prior to January 1, 2018, Abbott Green participants could contribute from 1% up to 50% of eligible earnings as pre-tax or Roth contributions.

 

7


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE A - DESCRIPTION OF THE PLAN - Continued

 

Contributions and Vesting - Continued

 

Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions.  Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

 

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2018 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

 

Effective as of August 1, 2018, participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year.  An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution.  Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

 

Employer contributions are invested according to the participant’s investment elections.

 

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

 

On January 1, 2013, Abbott separated into two publicly traded companies — Abbott and AbbVie Inc. (“AbbVie”).  The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution.  Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

 

8


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE A - DESCRIPTION OF THE PLAN - Continued

 

Contributions and Vesting - Continued

 

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

 

Participants are at all times fully vested in their own contributions and earnings thereon.  Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

 

 

 

Vesting

 

Service

 

percentage

 

 

 

 

 

Less than two years

 

0

%

Two years or more

 

100

%

 

For employees who became Abbott Green participants prior to January 1, 2018, employer contributions vest 20% after one year of service and 100% after two years of service.  Abbott Green participants are also fully vested in employer contributions upon disability.

 

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date.  Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time.  In 2018, forfeitures reduced Abbott’s employer contributions by approximately $5.3 million.  Approximately $361,000 and $257,000 in forfeitures were available at the end of 2018 and 2017, respectively.

 

Distributions and In-Service Withdrawals

 

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum.  Participants may elect a direct rollover of their accounts.  Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1st of April following the year the participant reaches age 70 ½ or, if earlier, the 31st of December following the year in which the participant dies.  Interest, dividends and other earnings will continue to accrue on such deferred amounts.

 

9


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE A - DESCRIPTION OF THE PLAN - Continued

 

Distributions and In-Service Withdrawals - Continued

 

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions.  Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

 

Notes Receivable from Participants

 

Participants may convert their vested account balances into one or two loans to themselves.  The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Internal Revenue Service (“IRS”) limitations and restrictions.  Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made.  Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner).  Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time.  Post-termination loan repayments are permitted.  For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

 

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Accounting

 

The financial statements have been prepared using the accrual basis of accounting.

 

10


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities.  Actual results may differ from those estimates.

 

Investment Valuation

 

The Plan offers a variety of investment options to participants.  Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

 

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

 

Common stock, mutual funds, REITs and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

 

Collective trust funds and Private 40-Act mutual funds - Valued at the NAV provided by the administrator of the fund.  The NAV is used as a practical expedient to estimate fair value.  The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.  Redemption from the funds is permitted daily.  The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the fund’s net assets during any 90-day period for any one shareholder.  In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the funds in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind.

 

Corporate debt and government debt - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held.  Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions.  Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

 

Certificate of deposit - Valued at amortized cost, which approximates fair value given the instruments’ short duration of less than 130 days.

 

11


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

 

Investment Valuation - Continued

 

Futures contracts

 

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy.  A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date.  Futures contracts are exchange-traded and settle daily.  Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract.  Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

 

As of December 31, 2018 and 2017, the Plan held futures contracts with a notional amount of approximately $2.5 million and $3.6 million, respectively.  Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts.  The fair value of these derivative contracts was not material at December 31, 2018 and 2017.  Changes in fair value are accounted for as investment income within net depreciation in fair value of investments and totaled approximately $545,000 for the year ended December 31, 2018.

 

Short sales

 

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy.  Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment.  To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer.  The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement.  The price at such time may be more or less than the price at which the investment was sold by the separately managed account.  When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

 

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2018 and 2017 (dollars in thousands):

 

12


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

 

 

Basis of Fair Value Measurement

 

 

 

2018

 

Quoted
Prices in
Active
Markets

 

Significant
Other
Observable
Inputs

 

Significant
Unobservable
Inputs

 

Measured at
NAV

 

Total

 

Assets - Investments:

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

$

3,845,703

 

$

 

$

 

$

 

$

3,845,703

 

Mutual funds

 

1,578,825

 

 

 

 

1,578,825

 

REITs

 

23,533

 

 

 

 

23,533

 

Collective trust funds

 

 

 

 

3,179,861

 

3,179,861

 

Corporate debt

 

 

260,227

 

 

 

260,227

 

Government debt

 

 

464,338

 

 

 

464,338

 

Certificate of deposit

 

 

4,400

 

 

 

4,400

 

Self-directed brokerage accounts

 

22,281

 

 

 

 

22,281

 

Private 40-Act mutual funds

 

 

 

 

428,633

 

428,633

 

Total investments at fair value

 

$

5,470,342

 

$

728,965

 

$

 

$

3,608,494

 

$

9,807,801

 

 

 

 

Basis of Fair Value Measurement

 

 

 

2018

 

Quoted
Prices in
Active
Markets

 

Significant
Other
Observable
Inputs

 

Significant
Unobservable
Inputs

 

Measured at
NAV

 

Total

 

Liabilities - Investments sold short:

 

 

 

 

 

 

 

 

 

 

 

Government debt

 

$

 

$

219,491

 

$

 

$

 

$

219,491

 

Total investments sold short at fair value

 

$

 

$

219,491

 

$

 

$

 

$

219,491

 

 

 

 

Basis of Fair Value Measurement

 

 

 

2017

 

Quoted
Prices in
Active
Markets

 

Significant
Other
Observable
Inputs

 

Significant
Unobservable
Inputs

 

Measured at
NAV

 

Total

 

Assets - Investments:

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

$

3,643,267

 

$

 

$

 

$

 

$

3,643,267

 

Mutual funds

 

1,524,835

 

 

 

 

1,524,835

 

REITs

 

26,683

 

 

 

 

26,683

 

Collective trust funds

 

 

 

 

2,155,331

 

2,155,331

 

Corporate debt

 

 

179,984

 

 

 

179,984

 

Government debt

 

 

33,755

 

 

 

33,755

 

Certificate of deposit

 

 

7,301

 

 

 

7,301

 

Private 40-Act mutual funds

 

 

 

 

324,544

 

324,544

 

Total investments at fair value

 

$

5,194,785

 

$

221,040

 

$

 

$

2,479,875

 

$

7,895,700

 

 

The Private 40-Act mutual funds are not direct filing entities.  These funds invest in fixed income instruments of varying maturities.  The investment objective of one fund is to seek maximum current income and the other is to seek maximum total return, both being consistent with preservation of capital and liquidity.

 

13


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

 

Notes Receivable from Participants

 

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest.  Delinquent loans are reclassified as distributions based upon the terms of the Plan.  No allowance for credit losses has been recorded as of December 31, 2018 or 2017.

 

Income Recognition

 

Purchases and sales of securities are recorded on a trade-date basis.  Interest income is recorded on an accrual basis.  Dividends are recorded on the ex-dividend date.  Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net depreciation in fair value of investments.

 

Administrative Expenses

 

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie stock.  Investment fees for mutual funds, collective trust, managed accounts and money market funds are charged against the net assets of the respective fund.  Abbott pays other record-keeping and administration fees, where applicable.

 

Payment of Benefits

 

Benefits are recorded when paid.

 

NOTE C - INVESTMENTS

 

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

 

A summary of Abbott common share data as of December 31, 2018 and 2017 is presented below:

 

 

 

2018

 

2017

 

Abbott common shares, 29,425,544 and 29,803,690 shares, respectively (dollars in thousands)

 

$

2,128,350

 

$

1,700,897

 

Market value per share

 

$

72.33

 

$

57.07

 

 

14


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE C — INVESTMENTS - Continued

 

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks.  Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

 

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

 

A significant portion of the Plan’s assets is invested in Abbott common shares.

 

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock.  These transactions qualify as permitted party-in-interest transactions.

 

NOTE E - PLAN TERMINATION

 

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee.  All participants’ account balances would become fully vested upon Plan termination.  Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant.  At the present time, Abbott has no intention of terminating the Plan.

 

NOTE F - TAX STATUS

 

The IRS has determined and informed Abbott by a letter dated May 19, 2017, that the Plan and related Trust are designed in accordance with applicable sections of the IRC.  The Plan has been amended since the applicable date of the determination letter.  However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

 

15


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2018 and 2017

 

NOTE F - TAX STATUS - Continued

 

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities.  The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2018 and 2017, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements.  The Plan is subject to routine audits by taxing jurisdictions.  There are currently no audits in progress.

 

NOTE G — SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from December 31, 2018 through the date these financial statements were issued.  There were no subsequent events that require recognition or additional disclosure in these financial statements.

 

16


Table of Contents

 

SUPPLEMENTAL SCHEDULE

 


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - employer securities

 

 

 

 

 

*ABBOTT LABORATORIES, common shares

 

 

 

$

2,128,350

 

 

 

 

 

 

 

Common stock

 

 

 

 

 

1ST HORIZON NATL CORP

 

 

 

130

 

5TH 3RD BANCORP

 

 

 

672

 

ABBVIE INC.

 

 

 

1,577,871

 

ACADIA HEALTHCARE CO INC COM

 

 

 

97

 

ACUITY BRANDS INC COM

 

 

 

200

 

ADIENT PLC ADIENT PLC LTD COM

 

 

 

62

 

ADT INC DEL COM

 

 

 

29

 

ADVANCE AUTO PTS INC COM

 

 

 

334

 

AECOM

 

 

 

180

 

AES CORP COM

 

 

 

417

 

AFFILIATED MANAGERS GROUP INC COM STK

 

 

 

223

 

AGCO CORP COM

 

 

 

158

 

AGILENT TECHNOLOGIES INC COM

 

 

 

937

 

AGIOS PHARMACEUTICALS INC COM

 

 

 

6

 

AGNC INVT CORP COM

 

 

 

395

 

AIR LEASE CORP CL A CL A

 

 

 

118

 

AKAMAI TECHNOLOGIES INC COM STK

 

 

 

27

 

ALASKA AIR GROUP INC COM

 

 

 

319

 

ALBEMARLE CORP COM

 

 

 

355

 

ALLEGHANY CORP DEL COM

 

 

 

345

 

ALLEGION PLC COMMON STOCK

 

 

 

57

 

ALLIANT ENERGY CORP COM

 

 

 

434

 

ALLY FINL INC COM

 

 

 

418

 

ALNYLAM PHARMACEUTICALS INC COM

 

 

 

32

 

AMDOCS ORD GBP0.01

 

 

 

365

 

AMER FINL GROUP INC OH COM STK

 

 

 

284

 

AMER NATL INS CO COM

 

 

 

40

 

AMERCO COM

 

 

 

100

 

AMEREN CORP COM

 

 

 

691

 

AMERICAN AIRLINES INC COM USD1

 

 

 

578

 

AMERICAN WTR WKS CO INC NEW COM

 

 

 

714

 

AMERIPRISE FINL INC COM

 

 

 

531

 

AMETEK INC NEW COM

 

 

 

544

 

ANALOG DEVICES INC COM

 

 

 

1,163

 

ANTERO RES CORP COM

 

 

 

47

 

APACHE CORP COM

 

 

 

409

 

APERGY CORP COM

 

 

 

91

 

APPLE HOSPITALITY REIT INC COM NEW

 

 

 

134

 

APTARGROUP INC COM

 

 

 

254

 

APTIV PLC COM USD

 

 

 

94

 

AQUA AMER INC COM

 

 

 

265

 

ARAMARK COM

 

 

 

308

 

ARCH CAPITAL GROUP COM STK

 

 

 

379

 

ARCHER-DANIELS-MIDLAND CO COM

 

 

 

997

 

ARCONIC INC COM

 

 

 

318

 

ARCOSA INC COM

 

 

 

58

 

ARDAGH GROUP S A

 

 

 

9

 

ARRIS

 

 

 

217

 

ARROW ELECTR INC COM

 

 

 

261

 

ASHLAND GLOBAL HLDGS INC COM

 

 

 

193

 

ASPEN INSURANCE

 

 

 

108

 

 

18


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

ASPEN TECHNOLOGY INC COM

 

 

 

14

 

ASSOCTD BANC-CORP COM

 

 

 

141

 

ASSURANT INC COM

 

 

 

202

 

ASSURED GUARANTY LTD COMMON STK

 

 

 

173

 

ATHENE HOLDING LTD

 

 

 

276

 

ATMOS ENERGY CORP COM

 

 

 

440

 

AUTODESK INC COM

 

 

 

197

 

AUTONATION INC COM

 

 

 

85

 

AUTOZONE INC COM

 

 

 

117

 

AVANGRID INC COM

 

 

 

122

 

AVNET INC COM

 

 

 

174

 

AXA EQUITABLE HLDGS INC COM

 

 

 

143

 

AXALTA COATING SYSTEMS LTD

 

 

 

130

 

AXIS CAPITAL HOLDINGS LTD

 

 

 

165

 

BALL CORP COM

 

 

 

669

 

BANK OZK COM

 

 

 

121

 

BANKUNITED INC

 

 

 

131

 

BEMIS CO INC COM

 

 

 

181

 

BERKLEY W R CORP COM

 

 

 

306

 

BERRY GLOBAL GROUP INC

 

 

 

136

 

BEST BUY INC COM STK

 

 

 

405

 

BGC PARTNERS INC CL A

 

 

 

62

 

BIO RAD LABS INC CL A

 

 

 

214

 

BK HAW CORP COM

 

 

 

121

 

BLOCK H & R INC COM

 

 

 

186

 

BLUEBIRD BIO INC COM

 

 

 

73

 

BOK FINL CORP COM NEW

 

 

 

84

 

BOOZ ALLEN HAMILTON HLDG CORP CL A COM STK

 

 

 

14

 

BORG WARNER INC COM

 

 

 

316

 

BRIGHT HORIZONS FA

 

 

 

44

 

BRIGHTHOUSE FINL INC COM

 

 

 

159

 

BROWN & BROWN INC COM

 

 

 

263

 

BRUKER CORP

 

 

 

78

 

BRUNSWICK CORP COM

 

 

 

158

 

BUNGE LTD

 

 

 

328

 

CABOT CORP COM

 

 

 

111

 

CABOT OIL & GAS CORP COM

 

 

 

113

 

CAESARS ENTERTAINMENT CORP

 

 

 

168

 

CAMPBELL SOUP CO COM

 

 

 

79

 

CARDINAL HLTH INC

 

 

 

579

 

CARLISLE COMPANIES INC COM

 

 

 

256

 

CARMAX INC COM

 

 

 

188

 

CASEYS GEN STORES INC COM

 

 

 

203

 

CATALENT INC COM

 

 

 

150

 

CBOE GLOBAL MARKETS INC

 

 

 

34

 

CBRE GROUP INC CL A

 

 

 

288

 

CELANESE CORP DEL COM SER A STK

 

 

 

192

 

CENTENE CORP DEL COM

 

 

 

118

 

CENTENNIAL RESOURCE DEVELOPMENT INC

 

 

 

88

 

CENTERPOINT ENERGY INC COM

 

 

 

617

 

CENTURYLINK INC COM

 

 

 

631

 

CERNER CORP COM

 

 

 

401

 

CF INDS HLDGS INC COM

 

 

 

437

 

CHARLES RIV LABORATORIES INTL INC COM

 

 

 

66

 

 

19


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

CHENIERE ENERGY INC COM NEW

 

 

 

182

 

CHESAPEAKE ENERGY CORP COM

 

 

 

82

 

CHURCH & DWIGHT INC COM

 

 

 

106

 

CIMAREX ENERGY CO COM

 

 

 

220

 

CIN FNCL CORP COM

 

 

 

518

 

CINEMARK HLDGS INC COM

 

 

 

167

 

CIT GROUP INC NEW COM NEW

 

 

 

176

 

CITIZENS FINL GROUP INC COM

 

 

 

606

 

CLEAN HBRS INC COM

 

 

 

111

 

CLOROX CO COM

 

 

 

113

 

CMS ENERGY CORP COM

 

 

 

609

 

CNA FNCL CORP COM

 

 

 

55

 

CNX RESOURCES CORPORATION COM

 

 

 

100

 

COHERENT INC COM

 

 

 

32

 

COLFAX CORP

 

 

 

77

 

COLUMBIA SPORTSWEAR CO COM

 

 

 

96

 

COM ALCOA CORPORATION

 

 

 

216

 

COMERICA INC COM

 

 

 

455

 

COMM BANCSHARES INC COM

 

 

 

244

 

COMMSCOPE HLDG CO INC COM

 

 

 

136

 

CONAGRA BRANDS INC

 

 

 

449

 

CONCHO RES INC COM STK

 

 

 

758

 

CONDUENT INC COM

 

 

 

88

 

CONS EDISON INC COM

 

 

 

1,038

 

CONTINENTAL RES INC COM

 

 

 

79

 

COOPER COS INC COM NEW

 

 

 

451

 

COPA HOLDINGS SA COM STK

 

 

 

107

 

CORELOGIC INC-W/I COM STK

 

 

 

43

 

CORNING INC COM

 

 

 

1,038

 

COTY INC COM CL A

 

 

 

133

 

CRANE CO COM

 

 

 

157

 

CREDIT ACCEP CORP MICH COM

 

 

 

15

 

CULLEN / FROST BANKERS INC COM

 

 

 

219

 

CUMMINS INC

 

 

 

554

 

CURTISS WRIGHT CORP COM

 

 

 

180

 

CYPRESS SEMICONDUCTOR CORP COM

 

 

 

62

 

D R HORTON INC COM

 

 

 

216

 

DARDEN RESTAURANTS INC COM

 

 

 

268

 

DAVITA INC COM

 

 

 

140

 

DELL TECHNOLOGIES INC COM

 

 

 

253

 

DENTSPLY SIRONA INC COM

 

 

 

354

 

DEVON ENERGY CORP NEW COM

 

 

 

459

 

DIAMONDBACK ENERGY INC COM

 

 

 

529

 

DICKS SPORTING GOODS INC

 

 

 

101

 

DISCOVER FINL SVCS COM STK

 

 

 

467

 

DISCOVERY INC - A

 

 

 

166

 

DISCOVERY INC

 

 

 

347

 

DISH NETWORK CORP CL A COM STK

 

 

 

241

 

DOLBY LABORATORIES INC CL A COM STK

 

 

 

168

 

DOLLAR TREE INC COM STK

 

 

 

767

 

DOMINION ENERGY

 

 

 

296

 

DOMTAR CORP

 

 

 

95

 

DONALDSON INC COM

 

 

 

16

 

DOVER CORP.

 

 

 

448

 

 

20


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

DTE ENERGY CO COM

 

 

 

869

 

DUN & BRADSTREET

 

 

 

130

 

DXC TECHNOLOGY CO COM

 

 

 

651

 

E TRADE FINL CORP

 

 

 

377

 

EAGLE MATLS INC COM

 

 

 

15

 

EAST WEST BANCORP INC COM

 

 

 

252

 

EASTMAN CHEM CO COM

 

 

 

449

 

ECANA CORP

 

 

 

81

 

ECHOSTAR CORPORATION

 

 

 

77

 

EDISON INTL COM

 

 

 

786

 

ELANCO ANIMAL HEALTH INC COM

 

 

 

53

 

ELASTIC N V

 

 

 

5

 

ELEMENT

 

 

 

51

 

ENERGIZER HLDGS INC NEW COM

 

 

 

50

 

ENTERGY CORP NEW COM

 

 

 

678

 

EPR PPTYS

 

 

 

206

 

EQT CORP COM

 

 

 

209

 

EQUIFAX INC COM

 

 

 

354

 

EQUITRANS MIDSTREAM CORP COM NPV WI

 

 

 

185

 

ERIE INDTY CO CL A

 

 

 

33

 

EURONET WORLDWIDE INC COM

 

 

 

109

 

EVEREST RE GROUP COM

 

 

 

232

 

EVERGY INC COM NPV

 

 

 

650

 

EVERSOURCE ENERGY COM

 

 

 

897

 

EXTENDED STAY AMER INC

 

 

 

52

 

EXTRACTION OIL & GAS INC EXTRACTION OIL & GAS LLC

 

 

 

20

 

F N B CORP PA COM

 

 

 

138

 

FIDELITY NATL FINL INC

 

 

 

362

 

FIDELITY NATL INFORMATION SVCS INC COM STK

 

 

 

1,335

 

FIREEYE INC COM

 

 

 

46

 

FIRST AMERN FINL CORP COM STK

 

 

 

212

 

FIRST HAWAIIAN INC COM

 

 

 

105

 

FIRST HORIZON NATL CORP COM

 

 

 

186

 

FIRST REP BK SAN FRANCISCO CALIF NEW COM

 

 

 

619

 

FIRST SOLAR INC COM

 

 

 

152

 

FIRSTENERGY CORP COM

 

 

 

796

 

FLIR SYS INC COM

 

 

 

232

 

FLOWERS FOODS INC COM

 

 

 

144

 

FLOWSERVE CORP COM

 

 

 

217

 

FLUOR CORP NEW COM

 

 

 

197

 

FMC CORP COM (NEW)

 

 

 

256

 

FOOT LOCKER INC COM

 

 

 

265

 

FORTIVE CORP

 

 

 

71

 

FORTUNE BRANDS HOME & SEC INC COM

 

 

 

137

 

FREEPORT-MCMORAN INC

 

 

 

650

 

FRKLN RES INC COM

 

 

 

389

 

GALLAGHER ARTHUR J & CO COM

 

 

 

579

 

GAP INC COM

 

 

 

227

 

GARDNER DENVER HLDGS INC COM

 

 

 

76

 

GARMIN LTD COMMON STOCK

 

 

 

314

 

GATES INDL CORP PL

 

 

 

25

 

GCI LIBERTY INC COM NPV CL A

 

 

 

180

 

GENESEE & WYO INC CL A CL A

 

 

 

150

 

GENPACT LIMITED

 

 

 

112

 

 

21


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

GENTEX CORP COM

 

 

 

76

 

GENUINE PARTS CO COM

 

 

 

598

 

GOODYEAR TIRE & RUBBER CO COM

 

 

 

207

 

GRACE W R & CO DEL NEW COM STK

 

 

 

49

 

GRAFTECH INTL LTD COM

 

 

 

29

 

GRAHAM HLDGS CO COM

 

 

 

117

 

GRAPHIC PACKAGING HLDG CO COM STK

 

 

 

119

 

HAIN CELESTIAL GROUP INC COM

 

 

 

63

 

HANOVER INS GROUP INC COM

 

 

 

215

 

HARLEY DAVIDSON

 

 

 

242

 

HARTFORD FINL SVCS GROUP INC COM

 

 

 

692

 

HASBRO INC COM

 

 

 

89

 

HAWAIIAN ELEC INDS INC COM

 

 

 

172

 

HD SUPPLY HLDGS INC. COM

 

 

 

213

 

HELMERICH & PAYNE INC COM

 

 

 

221

 

HENRY SCHEIN INC COMMON STOCK

 

 

 

443

 

HERBALIFE NUTRITION LTD COM STK

 

 

 

228

 

HERSHEY COMPANY

 

 

 

59

 

HESS CORP COM STK

 

 

 

462

 

HEXCEL CORP NEW COM

 

 

 

169

 

HILL-ROM HLDGS INC COM STK

 

 

 

90

 

HOLLYFRONTIER CORP COM

 

 

 

354

 

HOLOGIC INC COM

 

 

 

486

 

HORMEL FOODS CORP COM

 

 

 

505

 

HOWARD HUGHES CORP COM STOCK

 

 

 

98

 

HUBBELL INC COM

 

 

 

76

 

HUNTINGTON BANCSHARES INC COM

 

 

 

548

 

HUNTINGTON INGALLS INDS INC COM

 

 

 

51

 

HUNTSMAN CORP COM STK

 

 

 

183

 

HYATT HOTELS CORP

 

 

 

124

 

IDEX CORP COM

 

 

 

25

 

IHS MARKIT LTD COM

 

 

 

799

 

INGERSOLL-RAND PLC COM STK

 

 

 

447

 

INGREDION INC COM

 

 

 

282

 

INTEGRA LIFESCIENCES HLDG CORP

 

 

 

32

 

INTERACTIVE BROKERS GROUP INC CL COM

 

 

 

16

 

INTERNATIONAL GAME TECHNOLOGY

 

 

 

60

 

INTERPUBLIC GROUP COMPANIES INC COM

 

 

 

310

 

INTL FLAVORS & FRAGRANCES INC COM

 

 

 

309

 

INTL PAPER CO COM

 

 

 

638

 

INVESCO LTD

 

 

 

296

 

IQVIA HLDGS INC

 

 

 

825

 

ITT INC COM

 

 

 

183

 

JABIL INC

 

 

 

171

 

JACOBS ENGR GROUP INC COM

 

 

 

325

 

JAZZ PHARMACEUTICALS PLC

 

 

 

25

 

JEFFERIES FINL GROUP INC COM

 

 

 

220

 

JETBLUE AWYS CORP COM

 

 

 

213

 

JONES LANG LASALLE INC COM STK

 

 

 

250

 

JUNIPER NETWORKS INC COM

 

 

 

400

 

KAR AUCTION SVCS INC COM STK

 

 

 

18

 

KELLOGG CO

 

 

 

308

 

KEYCORP NEW COM

 

 

 

663

 

KEYSIGHT TECHNOLOGIES INC COM

 

 

 

506

 

 

22


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

KIRBY CORP COM

 

 

 

173

 

KNIGHT-SWIFT TRANSN HLDGS INC

 

 

 

138

 

KOHLS CORP COM

 

 

 

483

 

KOSMOS ENERGY LTD

 

 

 

33

 

KROGER CO COM

 

 

 

951

 

KS CY SOUTHN

 

 

 

426

 

L BRANDS INC COM

 

 

 

208

 

L3 TECHNOLOGIES INC COM

 

 

 

592

 

LAB CORP AMER HLDGS COM NEW

 

 

 

521

 

LAMAR ADVERTISING CO

 

 

 

23

 

LAMB WESTON HLDGS INC

 

 

 

469

 

LEAR CORP COM NEW COM NEW

 

 

 

307

 

LEGG MASON INC COM

 

 

 

94

 

LEGGETT & PLATT INC COM

 

 

 

205

 

LEIDOS HLDGS INC COM

 

 

 

324

 

LENNAR CORP CL A

 

 

 

227

 

LENNAR CORP CL B

 

 

 

10

 

LENNOX INTL INC COM

 

 

 

22

 

LIBERTY BROADBAND CORP COM SER A

 

 

 

80

 

LIBERTY BROADBAND CORP COM SER C

 

 

 

327

 

LIBERTY MEDIA CORP DEL COM SER A SIRIUSXM GROUP

 

 

 

135

 

LIBERTY MEDIA CORP DEL COM SER A FORMULAONE

 

 

 

32

 

LIBERTY MEDIA CORP DEL COM SER C SIRIUSXM GROUP

 

 

 

265

 

LIBERTY MEDIA CORPORATION COM SER C FORMULA

 

 

 

264

 

LINCOLN NATL CORP COM

 

 

 

477

 

LIONS GATE ENTMT CORP CL B

 

 

 

59

 

LIONS GATE ENTMT CORP VOTING SHARES CL A

 

 

 

31

 

LITTELFUSE INC COM

 

 

 

30

 

LKQ CORP

 

 

 

273

 

LOEWS CORP COM

 

 

 

552

 

LOGMEIN INC COM

 

 

 

61

 

M & T BK CORP COM

 

 

 

874

 

MACQUARIE INFRASTRUCTURE CORP

 

 

 

127

 

MACYS INC COM STK

 

 

 

397

 

MADISON SQUARE GARDEN CO

 

 

 

193

 

MANPOWERGROUP INC

 

 

 

174

 

MARATHON OIL CORP COM

 

 

 

518

 

MARKEL CORP HOLDING CO COM

 

 

 

561

 

MARTIN MARIETTA MATLS INC COM

 

 

 

38

 

MARVELL TECH GROUP

 

 

 

285

 

MASCO CORP COM

 

 

 

122

 

MATTEL INC

 

 

 

116

 

MC CORMICK & CO INC COM NON-VTG

 

 

 

695

 

MDU RES GROUP INC COM

 

 

 

202

 

MEDNAX INC COM

 

 

 

126

 

MERCURY GEN CORP NEW COM

 

 

 

62

 

MGM RESORTS INTERNATIONAL COM

 

 

 

474

 

MICHAEL KORS

 

 

 

107

 

MICHAELS COS INC COM

 

 

 

51

 

MIDDLEBY CORP COM

 

 

 

101

 

MLP LAZARD LTD CL A

 

 

 

16

 

MOHAWK INDS INC COM

 

 

 

317

 

MOLINA HEALTHCARE INC COM

 

 

 

49

 

MOLSON COORS BREWING COM CL B

 

 

 

425

 

 

23


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

MOSAIC CO/THE

 

 

 

447

 

MOTOROLA SOLUTIONS INC

 

 

 

721

 

MSC INDL DIRECT INC CL A COM

 

 

 

82

 

MURPHY OIL CORP COM

 

 

 

168

 

MYLAN NV

 

 

 

613

 

NABORS INDUSTRIES COM

 

 

 

31

 

NASDAQ INC

 

 

 

411

 

NATIONAL INSTRS CORP COM

 

 

 

42

 

NATIONAL OILWELL VARCO COM STK

 

 

 

428

 

NATL FUEL GAS CO COM

 

 

 

181

 

NAVIENT CORP COM

 

 

 

100

 

NCR CORP COM

 

 

 

21

 

NEW YORK CMNTY BANCORP INC COM

 

 

 

194

 

NEWELL BRANDS INC COM

 

 

 

351

 

NEWMARKET CORP COM

 

 

 

8

 

NEWMONT GOLDCORP CORPORATION

 

 

 

805

 

NEWS CORP COM CL A

 

 

 

190

 

NEWS CORP COM CL B

 

 

 

61

 

NIELSEN HOLDINGS PLC COMSTK

 

 

 

362

 

NISOURCE INC COM

 

 

 

400

 

NOBLE ENERGY INC COM

 

 

 

392

 

NORDSON CORP COM

 

 

 

19

 

*NORTHERN TR CORP COM

 

 

 

535

 

NORWEGIAN CRUISE LINE HLDGS LTD COM

 

 

 

405

 

NRG ENERGY INC COM NEW

 

 

 

500

 

NU SKIN ENTERPRISES INC CL A CL A

 

 

 

102

 

NUANCE COMMUNICATIONS INC COM

 

 

 

165

 

NUCOR CORP COM

 

 

 

709

 

NVENT ELECTRIC PLC

 

 

 

157

 

OGE ENERGY CORP COM

 

 

 

340

 

OLD REP INTL CORP COM

 

 

 

253

 

OLIN CORP COM

 

 

 

146

 

OMNICOM GROUP INC COM

 

 

 

241

 

ONEMAIN HLDGS INC COM

 

 

 

75

 

ONEOK INC COM STK

 

 

 

565

 

OSHKOSH CORPORATION

 

 

 

194

 

OWENS CORNING NEW COM STK

 

 

 

207

 

OWENS ILL INC COM NEW

 

 

 

119

 

PACCAR INC COM

 

 

 

855

 

PACWEST BANCORP DEL COM

 

 

 

178

 

PARKER-HANNIFIN CORP COM

 

 

 

707

 

PARSLEY ENERGY INC CL A

 

 

 

56

 

PATTERSON-UTI ENERGY INC COM

 

 

 

97

 

PBF ENERGY INC CL A

 

 

 

169

 

PENSKE AUTOMOTIVE GROUP INC COM STK

 

 

 

63

 

PENTAIR PLC COM STK

 

 

 

258

 

PEOPLES UTD FINL INC COM

 

 

 

233

 

PERKINELMER INC COM

 

 

 

376

 

PERRIGO COMPANY LIMITED

 

 

 

216

 

PG& E CORP COM

 

 

 

535

 

PILGRIMS PRIDE CORP

 

 

 

35

 

PINNACLE FINL PARTNERS INC COM

 

 

 

86

 

PINNACLE W. CAP CORP COM

 

 

 

414

 

PLURALSIGHT INC CL A

 

 

 

5

 

 

24


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

POPULAR INC COM

 

 

 

203

 

POST HLDGS INC COM STK

 

 

 

107

 

PPL CORP COM

 

 

 

891

 

PREMIER INC CL A

 

 

 

58

 

PRINCIPAL FINL GROUP INC COM STK

 

 

 

538

 

PROSPERITY BANCSHARES INC COM

 

 

 

180

 

PUB SERVICE ENTERPRISE GROUP INC COM

 

 

 

1,144

 

PULTE GROUP INC

 

 

 

197

 

PVH CORP

 

 

 

311

 

QEP RES INC COM STK

 

 

 

58

 

QIAGEN NV

 

 

 

333

 

QORVO INC COM

 

 

 

330

 

QUANTA SVCS INC COM

 

 

 

136

 

QUEST DIAGNOSTICS INC COM

 

 

 

492

 

QURATE RETAIL INC

 

 

 

353

 

RALPH LAUREN CORP CL A

 

 

 

244

 

RANGE RES CORP COM

 

 

 

88

 

RAYMOND JAMES FNCL INC COM STK

 

 

 

301

 

REALOGY HLDGS CORP COM

 

 

 

75

 

REGAL BELOIT CORP

 

 

 

132

 

REGIONS FINL CORP

 

 

 

603

 

REINSURANCE GROUP AMER INC

 

 

 

383

 

RELIANCE STL & ALUM CO COM

 

 

 

212

 

RENAISSANCE RE HLDGS LTD COM

 

 

 

211

 

REPUBLIC SVCS INC COM

 

 

 

639

 

ROPER TECHNOLOGIES, INC

 

 

 

958

 

ROYAL CARIBBEAN CRUISES COM STK

 

 

 

709

 

ROYAL GOLD INC

 

 

 

143

 

RPC INC COM

 

 

 

15

 

RPM INTL INC

 

 

 

267

 

RYDER SYS INC COM

 

 

 

109

 

SABRE CORP COM

 

 

 

50

 

SANTANDER CONSUMER USA HLDGS INC COM

 

 

 

77

 

SCHNEIDER NATL INC WIS CL B

 

 

 

32

 

SCOTTS MIRACLE-GRO

 

 

 

55

 

SEABOARD CORP DEL COM

 

 

 

39

 

SEALED AIR CORP NEW COM STK

 

 

 

108

 

SEMPRA ENERGY INC COM STK

 

 

 

1,291

 

SENSATA TECHNOLOGIES B V HOLDING

 

 

 

144

 

SERVICE CORP INTL COM

 

 

 

162

 

SIGNATURE BK NY N Y COM

 

 

 

90

 

SILGAN HLDGS INC COM

 

 

 

53

 

SKECHERS U S A INC CL A

 

 

 

68

 

SKYWORKS SOLUTIONS INC COM

 

 

 

152

 

SLM CORP COM

 

 

 

157

 

SM ENERGY CO COM

 

 

 

75

 

SMUCKER J M CO COM NEW

 

 

 

448

 

SNAP-ON INC COM

 

 

 

355

 

SOLARWINDS CORP COM

 

 

 

3

 

SONOCO PROD CO COM

 

 

 

228

 

SPECTRUM BRANDS HLDGS INC

 

 

 

41

 

SPRINT CORP COM SER 1

 

 

 

166

 

SS&C TECHNOLOGIES HLDGS INC COM

 

 

 

29

 

STANLEY BLACK & DECKER INC COM

 

 

 

789

 

 

25


Table of Contents

 

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2018

(Dollars in thousands)

 

Identity of party involved/

 

 

 

Current

 

Description of asset/ Rate/ Maturity

 

Cost (a)

 

value

 

 

 

 

 

 

 

Common stock - continued

 

 

 

 

 

STEEL DYNAMICS INC COM

 

 

 

244

 

STERICYCLE INC COM

 

 

 

132

 

STERIS PLC

 

 

 

390

 

STERLING BANCORP DEL COM

 

 

 

160

 

SUN TR BANKS INC COM

 

 

 

987

 

SVB FINANCIAL GROUP COMMON STOCK

 

 

 

101

 

SYMANTEC CORP COM

 

 

 

524

 

SYNCHRONY FINL COM

 

 

 

494

 

SYNOPSYS INC COM

 

 

 

493

 

SYNOVUS FINL CORP COM NEW

 

 

 

149

 

T ROWE PRICE GROUP INC

 

 

 

67

 

TAKE-TWO INTERACTIVE SOFTWARE INC

 

 

 

207

 

TAPESTRY INC

 

 

 

341

 

TARGA RES CORP COM

 

 

 

354

 

TCF FNCL CORP COM

 

 

 

140

 

TELEDYNE TECHNOLOGIES INC COM

 

 

 

318

 

TELEFLEX INC COM

 

 

 

415

 

TELEPHONE & DATA SYS INC COM STK

 

 

 

140

 

TERADATA CORP DEL COM STK

 

 

 

58

 

TERADYNE INC COM

 

 

 

206

 

TEREX CORP NEW COM

 

 

 

79

 

TEXTRON INC COM

 

 

 

406

 

TFS FINL CORP COM STK

 

 

 

34

 

THOR INDS INC COM STK

 

 

 

19

 

TIFFANY & CO COM

 

 

 

352

 

TIMKEN CO COM

 

 

 

111

 

TOLL BROS INC COM

 

 

 

96

 

TORCHMARK CORP COM

 

 

 

336

 

TRANSOCEAN LTD

 

 

 

156

 

TREEHOUSE FOODS INC COM

 

 

 

120

 

TRIBUNE MEDIA COMPANY CLASS A COMMON STOCK

 

 

 

173

 

TRIMBLE INC COM TRIMBLE INC

 

 

 

357

 

TRINITY IND INC COM

 

 

 

131

 

TX CAP BANCSHARES INC COM

 

 

 

41

 

TYSON FOODS INC CL A COM (DELAWARE)

 

 

 

677

 

U.S. CELLULAR CORP COM

 

 

 

30

 

UGI CORP NEW COM

 

 

 

401

 

UMPQUA HLDGS CORP COM

 

 

 

151

 

UNDER ARMOR INC CL A

 

 

 

34

 

UNDER ARMOUR INC CL C COM

 

 

 

32

 

UNITED CONTL HLDGS INC COM STK

 

 

 

892

 

UNITED STS STL CORP NEW COM

 

 

 

140

 

UNITED THERAPEUTICS CORP

 

 

 

204

 

UNIVAR INC COM

 

 

 

76

 

UNUM GROUP

 

 

 

266

 

UNVL HEALTH SERVICES INC CL B COM

 

 

 

424

 

US FOODS HLDG CORP COM

 

 

 

279

 

USG CORP